Objective-To evaluate the associations between the use of aspirin and the incidences of cardiovascular diseases, cancers, and other chronic diseases.
Introduction
In the United States vascular diseases account for about 1-2 million deaths, or half of all deaths each year. Recently, the results of a large clinical trial showing that regular use of aspirin may prevent myocardial infarction have received widespread publicity.' Given the preliminary nature of this published report, the limitation of the study to men, some evidence of internal inconsistency of the results, and the contradictory findings of other trials,' this relation cannot yet be considered secure.
As part of a prospective study on lifestyle practices and disease prevention in a retirement community in southern California, we assessed the association between regular use of analgesics containing aspirin and the incidence of several chronic diseases, including cardiovascular diseases and cancer.
Methods
In June 1981 a detailed health questionnaire was sent to all residents of Leisure World, Laguna Hills, a retirement community near Los Angeles, California. New residents who moved into the community after this date were sent the questionnaire in June 1982, June 1983, and October 1985. Residents of this community are almost always white, moderately affluent, and well educated, and about two thirds are women.
The health questionnaire requested information on previous medical diagnoses, including angina, acute myocardial infarction, hypertension, rheumatoid arthritis, and diabetes; height and weight; the use of drugs, including analgesics, laxatives, and vitamin supplements; the use of cigarettes and alcohol; exercise habits; dietary intake of certain foods; and for women menstrual and reproductive events, including use of oestrogen replacement treatment. The use of analgesics was ascertained from the questions: "Which of the following best describes your use of nonprescription pain medication? Several times a day, daily, weekly, monthly, less often or never" and "When you take non-prescription pain medication, what is the brand (for example, Empirin, Anacin, Bayer Aspirin) you usually take?"
The cohort was followed up for all hospital admissions to three hospitals serving the area (85% of these occur at one hospital immediately adjacent to the community) and for deaths with the death certificate records of the local health department. Death For analyses of the relation between cardiovascular disease and use of aspirin we excluded 1432 men and 1394 women who had reported a history of angina, myocardial infarction, or stroke in the initial survey (table II). The incidence of ischaemic heart disease was raised among daily users of aspirin compared with nonusers among both men and women (relative risk= 1-9, 1 1 to 3 1, p<0 05 and 1-7, 1 1 to 2-7, p<005, respectively). Except for "other heart disease" (including various diseases, the numerically most important of which was heart failure) in men, the use of aspirin was not significantly related to any other vascular disease examined. A 20-30% increased risk of stroke was, however, seen in men and women who took aspirin daily, but neither of these results was significant (sex and age adjusted relative risk= 1-3, 0-96 to I 7, p=0 10 for daily aspirin users compared with non-users). For all cardiovascular disease combined the risk was raised among daily users of aspirin compared with non-users among both men and women (relative risks= 1 5, 1 2 to 1-8, p<005 and 1-4, 1 2 to 1 7, p<0 05, respectively).
Other chronic diseases examined because of previous evidence of a possible association with regular use of aspirin included gastrointestinal bleeding, gastric ulcers, and cataracts (table III) . Among women, those who used aspirin less than daily showed a significant reduction in risk for ulcers (relative risk= 0-3, 0-14 to 0-74, p<005), but there was no evidence of a dose-response effect. No other result was significant or substantially different from unity. an even stronger association may exist between the regular use of aspirin and the development of renal cell carcinoma.
We are not aware of previous reports of an association between cancer of the colon and aspirin intake. Aspirin causes gastric irritation. In sufficiently high doses and combined with interference in absorption by foodstuffs in the intestinal lumen or through other mechanisms, aspirin might similarly affect the large bowel. Such irritation may lead to increased activity of mucosal stem cells and to an increased risk of cancer.
Evidence that regular administration of aspirin may be beneficial to patients with established coronary heart disease comes from several sources12-'5 and has been recently reviewed by the Antiplatelet Trialists' Collaboration.6 Overall, in 25 completed randomised trials of antiplatelet treatment (including aspirin) in patients with a history of transient ischaemic attack, occlusive stroke, unstable angina, or myocardial infarction allocation to antiplatelet treatment reduced mortality from vascular diseases by 15% but had no apparent effect on mortality from non-vascular diseases. There was no significant difference among the effects of the different types of antiplatelet treatment tested (300-325 mg aspirin daily, higher aspirin doses, sulphinpyrazone, or high dose aspirin with dipyridamole) or between the effects in patients with histories of cerebral or cardiac vascular diseases.
There have been two randomised trials of aspirin for the primary prevention of cardiovascular disease. The physicians' health study is a double blind, placebo controlled trial of 22 071 male doctors in the United States between the ages of 40 and 84. A primary aim of the study is to determine whether 325 mg aspirin taken every other day reduces mortality from and incidence of vascular disease.' 17After an average of 4 8 years of follow up there was no difference between the aspirin and placebo groups in total cardiovascular deaths (relative risk=0 99). The overall mortality from cardiovascular disease was extraordinarily and inexplicably low: 733 deaths expected v 88 observed. The patterns of risk of vascular disease associated with the regular use of aspirin in that study are strikingly similar to the patterns ofincidence in men in our study. The physicians' health study observed a 47% reduction in the overall risk of fatal and non-fatal myocardial infarction (relative risk=0 53, p<000001); we observed a non-significant reduction in risk of myocardial infarction of 36% and 27% among those who took aspirin daily and those who took it less often, respectively. For stroke there was a non-significant increase of 15% among those receiving aspirin in the physicians' health study (relative risk= l 15, p=0-41); our results indicate a 22% increase in risk associated with daily aspirin use. For deaths from ischaemic heart disease (data on morbidity were not reported) the relative risk was increased only slightly in the physicians' health study (relative risk= 1 08, p=0 81) compared with a substantially higher and significant increase observed in our study (relative risk=1 86). We presume, however, that the category "sudden death" in the physicians' health study (relative risk= 1 49) includes subjects with underlying ischaemic heart disease. The relative risk for "other" cardiovascular disease deaths (relative risk= 179) was also quite similar to that in our study (relative risk= 1 64).
The only other data on the role of aspirin in the primary prevention of cardiovascular disease derive from a randomised trial of 5139 British doctors that tested 500 mg of aspirin daily. '8 In contrast with the physicians' health study the British data showed no differences in risk of fatal or non-fatal myocardial infarction between those assigned to the aspirin and the control groups. Like the physicians' health study and our study, a slight but non-significant excess of strokes was observed among those assigped to the aspirin group. No difference was observed-in the mortality from all cardiovascular diseases.
Although aspirin treatment has proved benefit for those with a history of cardiovascular disease (secondary prevention), data from the two clinical trials combined with the results from our large prospective study suggest that the risk-benefit equation might balance differently for primary prevention. Though the reduction in mortality from acute myocardial infarction in the physicians' health study was significant, it was accompanied by small increases in mortality from other vascular diseases so that no overall reduction in mortality from vascular diseases was apparent. This observation is supported by data on mortality from the British study and from our data on the incidences of chronic disease. We extend these observations to show no reduction in incidence of vascular disease in women who use aspirin daily. In fact, our study found a significantly increased incidence of ischaemic heart disease in regular aspirin users of both sexes and an increased incidence of "other" heart disease, which was significant in men.
Gastrointestinal May 1987 May , 1954 consecutive women delivering at this hospital were entered in the study. We obtained detailed histories after getting informed consent and performed a thorough physical examination and collected 3-5 ml venous blood. Cord blood was taken from live and stillborn infants. The serum samples of mother, baby, and, in some cases, the father were tested for antibodies to HIV-I by enzyme linked immunosorbent assay (ELISA) and western blot analysis. We attempted to trace and follow up two groups: (a) all women positive for antibody to HIV-I and their infants and (b) 40 sets of women negative for antibody to HIV-I and their infants. All seropositive women and their spouses were counselled. Repeat venous blood samples were collected from mothers and infants in both the groups at 6-8, 12, 18 , and 24 months and tested for antibodies to HIV and a complete blood count was done. All children received vaccines: BCG at birth, oral polio and diphtheria, pertussis, and tetanus at 3, 4, and 5 months, and measles at 8 months.
Data were analysed by using X2 tests with epidemiologic software from the Centers for Disease Control.
Results
Of 1954 women screened at delivery, 227 (12%) were seropositive for HIV-I. The seropositive women were significantly younger with a mean (SD) age of (5-4) years (Student's t test p<005). The seronegative women had a mean (SD) age of 25-1 (7-7) years. Among seropositive women, 62 (27%) were primigravidas and 185 (82%) were married. Risk cofactors such as higher number of lifetime sexual partners (table I), single or divorced or widowed, higher  educational state (table II) , history of transfusion, travel abroad, and working (table III) were associated with high seroprevalence of HIV-I. Fifty two (23%) of the seropositive women had adverse outcomes compared with 227 (13%) of the seronegative women
